All the funding deals in the longevity market
Download our beautiful pitch about the longevity market
In our longevity market deck, you will find everything you need to understand the market
The longevity market is growing as more companies work on ways to extend healthy years of life.
We conducted deep research and collected 51 funding deals in the longevity market between 2024 and 2026.
We refresh this page very often so readers can follow new longevity market funding deals as the market changes.
And if you want to better understand this new industry, you should get our beautiful slides covering the longevity market.
Insights
- The longevity market has one very large outlier: Retro Biosciences raised $1.0B, which is larger than the next several disclosed rounds combined.
- The longevity market is not only about drugs. Clinics, diagnostics, supplements, AI health tools, and canine healthspan companies also attracted funding.
- Several longevity market companies raised again after 2024, including Function Health, GlycanAge, Aeovian Pharmaceuticals, and Loyal.
- Q4 2025 was the busiest period in this list, with many longevity market deals across diagnostics, AI, reprogramming, and consumer health.
- Large therapeutic rounds still dominate the longevity market by dollars, especially in reprogramming, mitochondrial biology, and age-related disease programs.
- Preventive health platforms are becoming a clear longevity market category, with Function Health, Fountain Life, Everlab, and Humanaut Health all raising capital.
- The longevity market is global. The list includes companies from the United States, Europe, India, Australia, and other regions.
- Diagnostics are a repeated theme in the longevity market, with companies measuring glycans, NAD, biological age, organ aging, and broad biomarker panels.
- Animal longevity is now part of the longevity market story, with Loyal raising capital through an FDA-regulated canine drug pathway.
This chart, featured in our longevity market deck, illustrates yearly VC funding for longevity startups
Summary table of the funding deals for the longevity market since 2024
We define the longevity market as products and services that use science, medicine, or technology to extend healthy years of life and slow or improve the effects of aging.
We include therapies, diagnostics, clinics, digital tools, supplements, and programs that are explicitly designed and marketed to improve healthspan, prevent age-related decline, or optimize long-term health.
We exclude generic healthcare, wellness, beauty, fitness, eldercare, and financial products that serve older adults but are not specifically focused on longevity or healthspan.
We focused exclusively on pure players, defined as companies with at least 70–80% of their business directly tied to the longevity market.
Our analysis has been done at a global level with a minimum funding threshold of $300k.
You can also read our detailed analysis to understand how funding activity in the longevity market has evolved recently.
If you want a longer-term view, we also have a study of how funding activity in the longevity market has changed over the years.
Also, you should know that we have a dedicated page, updated weekly, with all the latest fundraising deals in the longevity market.
| Name | What they do | Amount in $ | Quarter | Source(s) |
|---|---|---|---|---|
| HexemBio | Develops stem-cell rejuvenation therapy for age-related immune decline. | $10.4M | Q2 2026 | SOSV |
| Life Biosciences | Develops cellular rejuvenation therapies using partial epigenetic reprogramming. | $80.0M | Q2 2026 | Life Biosciences |
| L-Nutra | Creates nutrition programs for longevity and disease remission. | $36.5M | Q1 2026 | PR Newswire |
| Loyal | Develops FDA-regulated drugs to extend healthy lifespan in dogs. | $100.0M | Q1 2026 | Business Wire |
| TMRW | Runs longevity clinics and memberships using health data and testing. | $7.0M | Q1 2026 | Longevity.Technology |
| GlycanAge | Measures biological age and inflammaging through glycan biomarkers. | $8.7M | Q4 2025 | Longevity.Technology |
| Decode Age | Builds aging biology tools, biomarkers, and longevity supplements. | $1.7M | Q4 2025 | Entrackr |
| Aeovian Pharmaceuticals | Develops selective mTORC1 therapies for age-related diseases. | $55.0M | Q4 2025 | Business Wire |
| Cyclana Bio | Develops therapies for chronic inflammation using tissue models. | $6.6M | Q4 2025 | New Market Pitch |
| AAA LifeOS | Builds an AI platform for longevity and digital continuity. | $5.6M | Q4 2025 | FinancialContent |
| Function Health | Offers lab testing, imaging, and AI preventive health insights. | $298.0M | Q4 2025 | PR Newswire |
| Blueprint | Sells longevity supplements, diagnostics, prescriptions, and AI coaching. | $60.0M | Q4 2025 | Fitt Insider |
| Generation Lab | Measures biological aging across different organ systems. | $11.0M | Q4 2025 | PR Newswire |
| NewLimit | Develops reprogramming medicines to restore youthful cell function. | $45.0M | Q4 2025 | Ventureburn |
| Vincere Biosciences | Develops small molecules that restore mitophagy in aging disease. | $5.0M | Q4 2025 | New Market Pitch |
| Cirrus Therapeutics | Develops gene therapy for dry age-related macular degeneration. | $11.0M | Q4 2025 | New Market Pitch |
| Illimis Therapeutics | Develops TAM receptor therapies for Alzheimer’s and immune disease. | $42.0M | Q3 2025 | New Market Pitch |
| Jocasta Neuroscience | Develops Klotho protein therapy for cognitive decline and dementia. | $35.0M | Q3 2025 | New Market Pitch |
| MitoRx Therapeutics | Develops mitochondrial therapies for sulfide-signaling dysfunction. | $2.1M | Q3 2025 | New Market Pitch |
| Fountain Life | Runs AI-enabled preventive longevity clinics and diagnostics. | $18.0M | Q3 2025 | TechCrunch |
| Blue Longevity Clinic | Runs a clinic focused on longevity services. | $2.3M | Q3 2025 | Gaebler.com |
| Everlab | Offers AI-powered preventive health and longevity diagnostics. | $10.0M | Q3 2025 | Business Wire |
| Circulate Health | Runs plasma exchange centers and longevity research programs. | $12.0M | Q3 2025 | PR Newswire |
| Genflow Biosciences | Develops SIRT6 gene therapy to slow aging. | $4.3M | Q2 2025 | New Market Pitch |
| Biopeak | Offers preventive health and longevity services in India. | $3.0M | Q2 2025 | The Economic Times |
| Minovia Therapeutics | Develops mitochondrial augmentation therapies for age-related decline. | $180.0M | Q2 2025 | New Market Pitch |
| Juvenescence | Develops AI-enabled drugs targeting biological drivers of aging. | $76.0M | Q2 2025 | PharmiWeb.com |
| NewLimit | Develops age-reversing medicines through cellular reprogramming. | $130.0M | Q2 2025 | TechCrunch |
| Insilico Medicine | Uses AI to discover drugs for aging-related diseases. | $110.0M | Q1 2025 | PR Newswire |
| Loyal | Develops drugs to extend healthy lifespan in dogs. | $22.0M | Q1 2025 | Longevity.Technology |
| Junevity | Develops siRNA cell-reset therapies for diseases of aging. | $10.0M | Q1 2025 | Business Wire |
| Retro Biosciences | Develops reprogramming, autophagy, and plasma-inspired longevity therapies. | $1,000.0M | Q1 2025 | TechCrunch, FT |
| Grey Matter Neurosciences | Develops focused ultrasound technology for Alzheimer’s disease. | $14.0M | Q1 2025 | Newswire |
| Cambrian Bio | Builds drugs targeting biological drivers of aging. | $23.0M | Q1 2025 | Crain's NY, CB Insights |
| clock.bio | Decodes human rejuvenation biology and gene-therapy targets. | $5.3M | Q4 2024 | Business Wire |
| Arda Therapeutics | Develops cell-depletion therapies for aging-related pathogenic cells. | $43.0M | Q4 2024 | Arda Therapeutics |
| Integrated Biosciences | Uses synthetic biology and machine learning to find aging drugs. | $17.2M | Q4 2024 | Business Wire |
| HDAX Therapeutics | Develops HDAC6 therapies for neurological and cardiometabolic disease. | $3.2M | Q3 2024 | Business Wire |
| NADMED | Measures NAD and glutathione levels for personalized diagnostics. | $3.8M | Q3 2024 | Cision News |
| Human Longevity, Inc. | Runs AI-driven precision prevention and longevity care programs. | $39.8M | Q3 2024 | PR Newswire |
| Oisín Biotechnologies | Develops genetic medicines for age-related diseases and frailty. | $15.0M | Q3 2024 | FirstWord Pharma |
| Function Health | Offers biomarker testing and personalized preventive health insights. | $53.0M | Q2 2024 | MobiHealthNews |
| Alzheon | Develops oral Alzheimer’s therapies and neurodegenerative disease diagnostics. | $100.0M | Q2 2024 | Alzheon |
| Matter Bio | Develops drugs that protect genome integrity and healthy lifespan. | $7.0M | Q2 2024 | PR Newswire |
| Humanaut Health | Runs longevity clinics with diagnostics and membership-based care. | $8.7M | Q2 2024 | Business Wire |
| Rubedo Life Sciences | Targets senescent cells that drive aging and disease. | $40.0M | Q2 2024 | Business Wire |
| Aeovian Pharmaceuticals | Develops selective mTORC1 inhibitors for aging-related diseases. | $50.0M | Q1 2024 | PR Newswire |
| SENISCA | Develops RNA-based senotherapeutics for age-related disease. | $4.7M | Q1 2024 | SENISCA |
| PreemptiveAI | Builds AI models for health prediction from wearable signals. | $6.4M | Q1 2024 | PR Newswire |
| GlycanAge | Measures biological age through glycan biomarker testing. | $4.2M | Q1 2024 | EU-Startups |
| BioAge Labs | Develops therapies based on the biology of aging. | $170.0M | Q1 2024 | BioSpace |
| Vasa Therapeutics | Develops therapies for cardiovascular aging and frailty. | $6.0M | Q1 2024 | PR Newswire |
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
Related blog posts
- The latest developments shaping the longevity market
- The most recent news in the longevity market
- How large is the longevity market in reality?
- The most recent funding news in the longevity market
